InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
1.570
+0.010 (0.64%)
Oct 26, 2026, 12:25 PM EDT - Market open
InflaRx Revenue
InflaRx had revenue of -10.10K EUR in the twelve months ending June 30, 2026. In the year 2025, InflaRx had annual revenue of 29.33K, down -82.31%. That makes InflaRx the 47,994th largest company in the world by revenue and 7,371st in the United States.
Revenue (ttm)
-10.10K EUR
Revenue Growth
-82.31%
P/S Ratio
n/a
Revenue / Employee
-155 EUR
Employees
65
Market Cap
231.37M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29.33K | -136.46K | -82.31% |
| Dec 31, 2024 | 165.79K | 102.70K | 162.79% |
| Dec 31, 2023 | 63.09K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 215.72M |
| AC Immune | 21.67M |
| Keros Therapeutics | 15.01M |
| Sol-Gel Technologies | 1.80M |
| Palisade Bio | 500.00K |
| Vicore Pharma Holding AB | 412.09K |
| Lyell Immunopharma | 27.00K |
IFRX News
- 4 days ago - InflaRx to present pre-clinical izicopan data at Kidney Week 2026 - TheFly
- 4 days ago - InflaRx Highlights Izicopan's Therapeutic Potential at Kidney Week 2026 - GlobeNewsWire
- 24 days ago - InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026 - GlobeNewsWire
- 25 days ago - InflaRx appoints Alperovich as SVP, Global Head of Clinical Development - TheFly
- 25 days ago - InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development - GlobeNewsWire
- 5 weeks ago - InflaRx to Host Virtual Capital Markets Day - GlobeNewsWire
- 6 weeks ago - InflaRx Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 6 weeks ago - InflaRx initiated with a Buy at Needham - TheFly